Print this page
-
Video Education with Result Dependent dIsclosure (VERDI)
Protocol: 042207Principal Investigator:
-
Deborah L Toppmeyer
Applicable Disease Sites: Breast
Colon
Kidney
Melanoma, Skin
Ovary
Pancreas
Prostate
Soft Tissue -
A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients with Advanced Solid Tumors
Protocol: 052305Principal Investigator:
-
Eugenia Girda
Applicable Disease Sites: Other Female Genital -
A Phase 1 Clinical Study of NXP800 in Subjects with Advanced Cancers and Expansion in
Subjects with Ovarian Cancer
Protocol: 052306Principal Investigator:
-
Eugenia Girda
Applicable Disease Sites: Ovary -
A Phase II/III Trial of MEDI4736 (Durvalumab) and Chemotherapy for Patients with High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy.
Protocol: 082210Principal Investigator:
-
Saum Ghodoussipour
Applicable Disease Sites: Other Female Genital
Other Male Genital
Urinary Bladder -
A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-Oophorectomy to Reduce the Risk of Ovarian Cancer Among BRC1 Carriers.
Protocol: 102005Principal Investigator:
-
Eugenia Girda
Applicable Disease Sites: Ovary -
A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women with Recurrent or Persistent Uterine Serous Carcinoma
Protocol: 102104Principal Investigator:
-
Eugenia Girda
Applicable Disease Sites: Cervix
Corpus Uteri
Other Female Genital -
A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined with either Trastuzumab and Hyaluronidase-Oysk (HERCEPTIN HYLECTA) or Pertuzumab Trastuzumab and Hyaluronidase-ZZFX (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma.
Protocol: 102301Principal Investigator:
-
Eugenia Girda
Applicable Disease Sites: Other Female Genital -
A Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination with Gemcitabine in Adult Subjects with Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon OncoSignature® Status.
Protocol: 102302Principal Investigator:
-
Aliza Leiser
Applicable Disease Sites: Other Female Genital -
A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers.
Protocol: 102402Principal Investigator:
-
Aliza Leiser
Applicable Disease Sites: Ovary -
A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination With Palbociclib, a CDK4/6 Inhibitor, in Patients With HER2+ Gynecologic Cancers and Other Solid Tumors: A ComboMATCH Treatment Trial.
Protocol: 102403Principal Investigator:
-
Eugenia Girda
Applicable Disease Sites: Any Site
Other Female Genital -
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors.
Protocol: 111702Principal Investigator:
-
Archana Sharma
Applicable Disease Sites: Any Site
Ovary
Prostate -
A Randomized Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Metastatic Germ Cell Tumors.
Protocol: 111904Principal Investigator:
-
Scott A Moerdler
Applicable Disease Sites: Other Female Genital
Other Male Genital -
Web-Based Coping and Communication Skills Intervention for Women who are newly diagnosed with Gynecological Cancer: A Pilot Study.
Protocol: 131908Principal Investigator:
-
Sharon Manne
Applicable Disease Sites: Cervix
Ovary -
Personalized Oncology Promoting Equity for Black Lives (PROPEL)
Protocol: 132309Principal Investigator:
-
Anita Y Kinney
Applicable Disease Sites: Breast
Colon
Corpus Uteri
Ovary
Pancreas
Prostate -
A Feasibility Study of E7 TCR-T Cell Induction Therapy for Locoregionally Advanced HPV-Associated Cancers
Protocol: 192104Principal Investigator:
-
Christian Hinrichs
Applicable Disease Sites: Breast
Cervix
Lip, Oral Cavity and Pharynx
Other Female Genital
Other Male Genital
Stomach -
A Phase II Trial of T Cell Receptor Gene Therapy Targeting HPV-16 E7 for HPV-Associated Cancers.
Protocol: 192204Principal Investigator:
-
Christian Hinrichs
Applicable Disease Sites: Anus
Cervix
Larynx
Lip, Oral Cavity and Pharynx
Other Female Genital
Other Male Genital